| 1 |
32496149 | Drug metabolising enzyme polymorphisms and chemotherapy-related ovarian failure in young breast cancer survivors. | 2021 Apr |
2 |
| 2 |
34114066 | Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients. | 2021 Sep |
1 |
| 3 |
30500380 | Metabolic activity testing can underestimate acute drug cytotoxicity as revealed by HepG2 cell clones overexpressing cytochrome P450 2C19 and 3A4. | 2019 Jan 15 |
1 |
| 4 |
28976264 | Epistatic interactions among CYP2C19*2, CYP3A4 and GSTP1 on the cyclophosphamide therapy in lupus nephritis patients. | 2017 Oct |
2 |
| 5 |
26456622 | Genetic markers in CYP2C19 and CYP2B6 for prediction of cyclophosphamide's 4-hydroxylation, efficacy and side effects in Chinese patients with systemic lupus erythematosus. | 2016 Feb |
1 |
| 6 |
26894931 | Cyclophosphamide treatment-induced leukopenia rates in ANCA-associated vasculitis are influenced by variant CYP450 2C9 genotypes. | 2016 Mar |
1 |
| 7 |
27991432 | The effect of proton pump inhibitors on the CYP2C19 enzyme activity evaluated by the pantoprazole-13C breath test in GERD patients: clinical relevance for personalized medicine. | 2016 Dec 17 |
1 |
| 8 |
26159874 | CYP2C19 Phenoconversion by Routinely Prescribed Proton Pump Inhibitors Omeprazole and Esomeprazole: Clinical Implications for Personalized Medicine. | 2015 Sep |
1 |
| 9 |
24768782 | Significant role of CYP450 genetic variants in cyclophosphamide based breast cancer treatment outcomes: a multi-analytical strategy. | 2014 Jul 1 |
1 |
| 10 |
21741706 | Correlation of CYP2B6, CYP2C19, ABCC4 and SOD2 genotype with outcomes in allogeneic blood and marrow transplant patients. | 2012 Jan |
2 |
| 11 |
20358205 | Pharmacogenetics of cyclophosphamide and CYP2C19 polymorphism in Thai systemic lupus erythematosus. | 2011 Sep |
4 |
| 12 |
21543025 | Cytochrome P450 polymorphisms and the response of lupus nephritis to cyclophosphamide therapy. | 2011 May |
1 |
| 13 |
21108329 | Allelic variations in CYP2B6 and CYP2C19 and survival of patients receiving cyclophosphamide prior to myeloablative hematopoietic stem cell transplantation. | 2010 Dec |
1 |
| 14 |
21175440 | The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation. | 2010 Dec |
3 |
| 15 |
18496131 | Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. | 2008 Jun |
1 |
| 16 |
18854824 | CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotype. | 2008 Oct 21 |
2 |
| 17 |
17407229 | Cytochrome P450 polymorphism as a predictor of ovarian toxicity to pulse cyclophosphamide in systemic lupus erythematosus. | 2007 Apr |
1 |
| 18 |
16183265 | Pharmacogenetics of cyclophosphamide in patients with hematological malignancies. | 2006 Jan |
1 |
| 19 |
16550168 | Cytochrome P450 pharmacogenetics and cancer. | 2006 Mar 13 |
1 |
| 20 |
16116487 | Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19. | 2005 |
1 |
| 21 |
15248218 | Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. | 2004 Jul |
1 |
| 22 |
12684728 | Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes. | 2003 Jun |
3 |
| 23 |
9241661 | Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. | 1997 Jun |
6 |